Lv2
140 积分 2023-11-29 加入
Proximod as a potential therapy for rheumatoid arthritis
9小时前
求助中
Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial
9小时前
已完结
Mini-PBPK-Based Population Model and Covariate Analysis to Assess the Complex Pharmacokinetics and Pharmacodynamics of RO7449135, an Anti-KLK5/KLK7 Bispecific Antibody in Cynomolgus Monkeys
2个月前
已完结
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
2个月前
已完结
Gut-directed therapeutics in inflammatory bowel disease
5个月前
已完结
Potent and Selective RIPK1 Inhibitors Targeting Dual‐Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis
6个月前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
8个月前
已完结
Ozanimod for Ulcerative Colitis
8个月前
已完结
Ulcerative Colitis in Adults
8个月前
已完结
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
8个月前
已完结
皖公网安备34019202002308
